person · Reporting owner
MILLER MICHAEL PATRICK
Disclosed activity across 4 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BioXcel Therapeutics, Inc.BTAI · Entity 8380 | Director | January 09, 2026 | January 13, 2026 |
| Jazz Pharmaceuticals plcJAZZ · Entity 818 | EVP, US Commercial | March 12, 2020 | March 13, 2020 |
| PUMA BIOTECHNOLOGY, INC.PBYI · Entity 5478 | Director | June 11, 2026 | June 16, 2026 |
| RIGEL PHARMACEUTICALS INCRIGL · Entity 2423 | Director | May 15, 2026 | May 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BioXcel Therapeutics, Inc.
Report date January 09, 2026 · Filed January 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.01 · Expires 2036-01-09 | Direct | 17,000 |
Reported balance
After 2026-01-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-09 · Grant · Acquired 17,000 · Balance 17,000 F1: The option shall vest and become exercisable on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case, subject to the Reporting Person's continuing in service as a non-employee director through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest and become exercisable on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case, subject to the Reporting Person's continuing in service as a non-employee director through such vesting date.
Jazz Pharmaceuticals plc
Report date March 12, 2020 · Filed March 13, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 22,118 |
Reported balance
After 2020-03-12 transaction · row 1
1 source rowRow 1 · 2020-03-12 · Sale · Disposed 1,500 · Balance 22,118 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
PUMA BIOTECHNOLOGY, INC.
Report date June 11, 2026 · Filed June 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 81,000 |
Reported balance
After 2026-06-11 transaction · row 1
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 27,000 · Balance 81,000 F1: Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer.
RIGEL PHARMACEUTICALS INC
Report date May 15, 2026 · Filed May 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,937 |
Reported balance
After 2026-05-15 transaction · row 1
1 source rowRow 1 · 2026-05-15 · Grant · Acquired 5,750 · Balance 5,937 F1: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 26, 2018 Filed Feb 28, 2018 22:27 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 940 | $147.44 | $138,593.60 |
DisclosureSEC source: 0001232524-18-000028 · edgardoc.xml · nonDerivative · entry 1 MILLER MICHAEL PATRICK · CIK 0001236514 · EVP, US Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,529 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| February 23, 2018 Filed Feb 27, 2018 22:30 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantStock Option (Right to Buy) · Derivative | 17,626 | $0.00 Strike: $68.25 | $0.00 |
DisclosureSEC source: 0001209191-18-014045 · doc4.xml · derivative · entry 1 MILLER MICHAEL PATRICK · CIK 0001236514 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,626 Underlying: Common Stock · 17,626 shares Expires 2028-02-22 F1 · derivative.exercise_date: The vesting commencement date ("Vesting Commencement Date") of the option is February 23, 2018. The option vests (i) with respect to one-third (1/3) of the shares underlying the option on the first anniversary of the Vesting Commencement Date and (ii) with respect to 1/36th of the shares underlying the option, on each monthly anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date. Read SEC document |
| February 14, 2018 Filed Feb 16, 2018 22:31 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 200 | $139.99 | $27,998.00 |
DisclosureSEC source: 0001601583-18-000004 · edgardoc.xml · nonDerivative · entry 1 MILLER MICHAEL PATRICK · CIK 0001236514 · EVP, US Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,469 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| January 12, 2018 Filed Jan 17, 2018 21:55 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 200 | $148.65 | $29,730.00 |
DisclosureSEC source: 0001232524-18-000004 · edgardoc.xml · nonDerivative · entry 1 MILLER MICHAEL PATRICK · CIK 0001236514 · EVP, US Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,669 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| December 11, 2017 Filed Dec 13, 2017 22:56 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 200 | $139.15 | $27,830.00 |
DisclosureSEC source: 0001232524-17-000187 · edgardoc.xml · nonDerivative · entry 1 MILLER MICHAEL PATRICK · CIK 0001236514 · EVP, US Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,869 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 73 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on November 30, 2017. Read SEC document |
| August 15, 2017 Filed Aug 16, 2017 23:17 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 200 | $144.38 | $28,876.00 |
DisclosureSEC source: 0001232524-17-000156 · edgardoc.xml · nonDerivative · entry 1 MILLER MICHAEL PATRICK · CIK 0001236514 · EVP, US Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,996 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| July 17, 2017 Filed Jul 18, 2017 22:19 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 200 | $154.97 | $30,994.00 |
DisclosureSEC source: 0001232524-17-000123 · edgardoc.xml · nonDerivative · entry 1 MILLER MICHAEL PATRICK · CIK 0001236514 · EVP, US Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,196 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 173 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on May 31, 2017. Read SEC document |
| June 15, 2017 Filed Jun 16, 2017 21:26 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 200 | $150.65 | $30,130.00 |
DisclosureSEC source: 0001232524-17-000121 · edgardoc.xml · nonDerivative · entry 1 MILLER MICHAEL PATRICK · CIK 0001236514 · EVP, US Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,223 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| May 15, 2017 Filed May 15, 2017 21:26 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 200 | $152.98 | $30,596.00 |
DisclosureSEC source: 0001232524-17-000115 · edgardoc.xml · nonDerivative · entry 2 MILLER MICHAEL PATRICK · CIK 0001236514 · EVP, US Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,423 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| May 11, 2017 Filed May 15, 2017 21:26 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $155.18 | $0.00 |
DisclosureSEC source: 0001232524-17-000115 · edgardoc.xml · derivative · entry 3 MILLER MICHAEL PATRICK · CIK 0001236514 · EVP, US Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Ordinary Shares · 2,500 shares Expires 2027-05-10 F3 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, May 11, 2017, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| May 11, 2017 Filed May 15, 2017 21:26 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001232524-17-000115 · edgardoc.xml · nonDerivative · entry 1 MILLER MICHAEL PATRICK · CIK 0001236514 · EVP, US Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,623 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of June 5, 2017, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. Read SEC document |
| May 05, 2017 Filed May 8, 2017 22:05 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 939 | $159.06 | $149,357.34 |
DisclosureSEC source: 0001232524-17-000100 · edgardoc.xml · nonDerivative · entry 1 MILLER MICHAEL PATRICK · CIK 0001236514 · EVP, US Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,623 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| April 17, 2017 Filed Apr 19, 2017 21:26 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 200 | $152.56 | $30,512.00 |
DisclosureSEC source: 0001232524-17-000085 · primary_doc.xml · nonDerivative · entry 1 MILLER MICHAEL PATRICK · CIK 0001236514 · SVP, US Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,562 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| March 15, 2017 Filed Mar 16, 2017 21:35 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 200 | $137.89 | $27,578.00 |
DisclosureSEC source: 0001232524-17-000079 · edgardoc.xml · nonDerivative · entry 1 MILLER MICHAEL PATRICK · CIK 0001236514 · SVP, US Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,762 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| March 02, 2017 Filed Mar 6, 2017 23:53 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 17,848 | $0.00 Strike: $136.18 | $0.00 |
DisclosureSEC source: 0001232524-17-000060 · edgardoc.xml · derivative · entry 3 MILLER MICHAEL PATRICK · CIK 0001236514 · SVP, US Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,848 Underlying: Ordinary Shares · 17,848 shares Expires 2027-03-01 F2 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, March 2, 2017, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| March 02, 2017 Filed Mar 6, 2017 23:53 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantIncentive Stock Option (right to buy) · Derivative | 902 | $0.00 Strike: $136.18 | $0.00 |
DisclosureSEC source: 0001232524-17-000060 · edgardoc.xml · derivative · entry 2 MILLER MICHAEL PATRICK · CIK 0001236514 · SVP, US Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 902 Underlying: Ordinary Shares · 902 shares Expires 2027-03-01 F2 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, March 2, 2017, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| March 02, 2017 Filed Mar 6, 2017 23:53 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001232524-17-000060 · edgardoc.xml · nonDerivative · entry 1 MILLER MICHAEL PATRICK · CIK 0001236514 · SVP, US Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,962 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2017, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 22:15 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 1,024 | $136.97 | $140,257.28 |
DisclosureSEC source: 0001232524-17-000036 · edgardoc.xml · nonDerivative · entry 1 MILLER MICHAEL PATRICK · CIK 0001236514 · SVP, US Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,462 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| February 15, 2017 Filed Feb 16, 2017 22:13 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 200 | $134.55 | $26,910.00 |
DisclosureSEC source: 0001232524-17-000006 · edgardoc.xml · nonDerivative · entry 1 MILLER MICHAEL PATRICK · CIK 0001236514 · SVP, US Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,486 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| January 17, 2017 Filed Jan 18, 2017 23:32 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 200 | $115.93 | $23,186.00 |
DisclosureSEC source: 0001232524-17-000002 · edgardoc.xml · nonDerivative · entry 1 MILLER MICHAEL PATRICK · CIK 0001236514 · SVP, US Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,686 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| December 15, 2016 Filed Dec 16, 2016 22:09 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 200 | $103.09 | $20,618.00 |
DisclosureSEC source: 0001232524-16-000392 · edgardoc.xml · nonDerivative · entry 1 MILLER MICHAEL PATRICK · CIK 0001236514 · SVP, US Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,886 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 161 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on November 30, 2016. Read SEC document |
| November 15, 2016 Filed Nov 16, 2016 22:11 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 200 | $112.19 | $22,438.00 |
DisclosureSEC source: 0001232524-16-000388 · edgardoc.xml · nonDerivative · entry 1 MILLER MICHAEL PATRICK · CIK 0001236514 · SVP, US Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,925 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| October 17, 2016 Filed Oct 18, 2016 21:14 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 200 | $118.16 | $23,632.00 |
DisclosureSEC source: 0001232524-16-000374 · edgardoc.xml · nonDerivative · entry 1 MILLER MICHAEL PATRICK · CIK 0001236514 · SVP, US Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,125 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| September 19, 2016 Filed Sep 20, 2016 21:34 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 200 | $126.17 | $25,234.00 |
DisclosureSEC source: 0001232524-16-000364 · edgardoc.xml · nonDerivative · entry 1 MILLER MICHAEL PATRICK · CIK 0001236514 · SVP, US Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,325 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.